| Literature DB >> 26206311 |
Ines Frederix1, Dominique Hansen, Karin Coninx, Pieter Vandervoort, Dominique Vandijck, Niel Hens, Emeline Van Craenenbroeck, Niels Van Driessche, Paul Dendale.
Abstract
BACKGROUND: Cardiac telerehabilitation has been introduced as an adjunct or alternative to conventional center-based cardiac rehabilitation to increase its long-term effectiveness. However, before large-scale implementation and reimbursement in current health care systems is possible, well-designed studies on the effectiveness of this new additional treatment strategy are needed.Entities:
Keywords: Internet; eHealth; effectiveness; telemedicine
Mesh:
Year: 2015 PMID: 26206311 PMCID: PMC4528085 DOI: 10.2196/jmir.4799
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Figure 1CONSORT patient flow diagram. IPAQ: International Physical Activity Questionnaire.
Baseline demographics, clinical characteristics, and medication use (N=140).
| Characteristic | Intervention group (n=69) | Control group (n=70) |
| ||
| Age (years), mean (SD) | 61 (9) | 61 (8) | .95 | ||
|
|
|
| .38 | ||
|
| Female | 10 (14) | 15 (21) |
| |
|
| Male | 59 (96) | 55 (79) |
| |
|
|
|
| .53 | ||
|
| Coronary artery disease | 65 (94) | 65 (93) |
| |
|
| Heart failure with reduced ejection fraction | 2 (3) | 4 (6) |
| |
|
| Heart failure with preserved ejection fraction | 2 (3) | 1 (1) |
| |
|
|
|
| .10 | ||
|
| I | 54 (78) | 61 (87) |
| |
|
| II | 12 (18) | 4 (6) |
| |
|
| III | 3 (4) | 5 (7) |
| |
|
|
|
| .32 | ||
|
| >50% | 52 (75) | 50 (71) |
| |
|
| 35%-50% | 0 (0) | 3 (4) |
| |
|
| <35% | 17 (25) | 17 (24) |
| |
|
|
|
|
| ||
|
| Atrial fibrillation | 5 (7) | 6 (9) | .99 | |
|
| Diabetes mellitus | 17 (25) | 19 (27) | .85 | |
|
| Hyperlipidemia | 53 (77) | 55 (79) | .84 | |
|
| Arterial hypertension | 40 (60) | 44 (63) | .61 | |
|
| Family history of cardiac disease | 34 (49) | 36 (51) | .87 | |
|
| Peripheral artery disease | 8 (12) | 11 (16) | .62 | |
|
|
|
| .99 | ||
|
| Current smoker | 18 (26) | 18 (26) |
| |
|
| Prior smoker | 22 (32) | 23 (33) |
| |
|
| Nonsmoker | 29 (42) | 29 (41) |
| |
| Body mass index (kg/m2), mean (SD) | 28 (5) | 28 (4) | .54 | ||
|
|
|
|
| ||
|
| On beta blocker | 53 (77) | 57 (81) | .61 | |
|
| On ACE-inhibitor | 44 (64) | 48 (69) | .72 | |
|
| On statin | 66 (96) | 64 (91) | .16 | |
|
|
|
|
| .88 | |
|
|
| Dual antiplatelet therapy | 37 (54) | 40 (57) |
|
|
|
| Antiplatelet monotherapy | 29 (42) | 27 (39) |
|
|
|
| No antiplatelet therapy | 3 (4) | 3 (4) |
|
|
| On diuretics | 12 (17) | 14 (20) | .76 | |
|
| On oral antidiabetics | 10 (15) | 10 (14) | .94 | |
|
| On insulin | 7 (10) | 5 (7) | .51 | |
|
| On anticoagulative therapy | 4 (6) | 5 (7) | .76 | |
|
| On antiarrhythmics | 4 (6) | 3 (4) | .67 | |
aNYHA: New York Heart Association.
Cardiopulmonary exercise test parameters at baseline and 6 weeks and 24 weeks follow-up period.
| Cardiopulmonary exercise test resultsa | Week, mean (SD) | Within-group, | Between-group, | |||||||||
|
| Week 1 | Week 6 | Week 24 | Overall | Δ 6-1 | Δ 24-6 | Δ 24-1 | Overall | Δ 6-1 | Δ 24-6 | Δ 24-1 | |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
| VO2 peak (mL/[min*kg]) | 22.46 (6.43) | 23.91 (6.74) | 24.46 (7.57) | .01 | .08 | .38 | .01 | <.001 | .19 | .01 | <.001 |
|
| HR max (% pred) | 79 (13) | 80 (12) | 83 (12) | .047 | .99 | .36 | .05 | .53 | N/A | N/A | N/A |
|
| Watt (W) | 152 (48) | 163 (52) | 165 (53) | .01 | .02 | .81 | .01 | .01 | .90 | .01 | .02 |
|
| Watt (pred%) | 103 (23) | 110 (27) | 116 (27) | <.001 | .01 | .27 | <.001 | <.001 | .83 | .01 | .01 |
|
| VT1 (W) | 69 (24) | 75 (25) | 81 (26) | <.001 | .74 | <.001 | <.001 | <.001 | .80 | <.001 | <.001 |
|
| VT1 (bpm) | 93 (17) | 91 (15) | 96 (15) | .01 | .99 | .01 | .08 | .01 | .35 | .01 | .047 |
|
| OUES (mL/min/log[mL/min]) | 2067 (518) | 2241 (545) | 2272 (579) | <.001 | .02 | .045 | <.001 | .1 | N/A | N/A | N/A |
|
| Weight (kg) | 83.3 (18.2) | 83.2 (17.4) | 83.0 (17.3) | .69 | N/A | N/A | N/A | .45 | N/A | N/A | N/A |
|
| BMI (kg/m2) | 28 (5) | 28 (5) | 28 (5) | .63 | N/A | N/A | N/A | .60 | N/A | N/A | N/A |
|
| DBP rest (mm Hg) | 82 (19) | 81 (21) | 77.24 (21.13) | .48 | N/A | N/A | N/A | .67 | N/A | N/A | N/A |
|
| SBP rest (mm Hg) | 126 (21) | 129 (30) | 150 (140) | .26 | N/A | N/A | N/A | .30 | N/A | N/A | N/A |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
| VO2 peak (mL/([min*kg]) | 22.72 (6.05) | 22.86 (5.37) | 22.15 (5.83) | .02 | .99 | .02 | .09 |
|
|
|
|
|
| HR max (% pred) | 77 (12) | 79 (13) | 79 (12) | .43 | N/A | N/A | N/A |
|
|
|
|
|
| Watt (W) | 150 (49) | 158 (50) | 152 (53) | .01 | <.001 | .02 | .99 |
|
|
|
|
|
| Watt (pred%) | 105 (26) | 108 (26) | 104 (27) | .01 | <.001 | .01 | .99 |
|
|
|
|
|
| VT1 (W) | 83 (34) | 88 (34) | 76 (31) | <.001 | .20 | <.001 | .01 |
|
|
|
|
|
| VT1 (bpm) | 95 (15) | 96 (15) | 95 (17) | .53 | N/A | N/A | N/A |
|
|
|
|
|
| OUES (mL/min/log[mL/min]) | 2493 (2338) | 2264 (637) | 2142 (636) | .25 | N/A | N/A | N/A |
|
|
|
|
|
| Weight (kg) | 82.7 (13.4) | 82.5 (13.3) | 82.5 (13.9) | .18 | N/A | N/A | N/A |
|
|
|
|
|
| BMI (kg/m2) | 28 (4) | 28 (4) | 27 (5) | .51 | N/A | N/A | N/A |
|
|
|
|
|
| DBP rest (mm Hg) | 84 (21) | 78 (19) | 79 (17) | .33 | N/A | N/A | N/A |
|
|
|
|
|
| SBP rest (mm Hg) | 129 (25) | 127 (23) | 129 (21) | .57 | N/A | N/A | N/A |
|
|
|
|
a BMI: body mass index; CPET: cardiopulmonary exercise testing; DBP: diastolic blood pressure; HR: heart rate; N/A: not applicable; OUES: oxygen uptake efficiency slope; SBP: systolic blood pressure; VT1: first ventilatory threshold.
Figure 2Line charts depicting (A) mean VO2 peak (mL/[min*kg]), (B) mean Watt (% predicted), (C) median total daily steps, (D) median vigorous-moderate-walking (VMW) activity for all domains (MET-min/week), (E) median VMW activity for leisure time (MET-min/week), (F) median sitting time (min/week) for week 1, week 6, and week 24, respectively. Intervention group is represented by the heart icon; control group by the building icon. *P<.05, ** P<.001.
Results from HeartQol questionnaire at baseline and after 6 weeks and 24 weeks of follow-up.
| Score | Intervention groupa | Control groupa |
| |||||||||
|
| Baseline | Week 6 | Week 24 |
| SRM | Baseline | Week 6 | Week 24 |
| SRM |
| |
|
|
|
|
|
|
|
|
| |||||
|
| Mean (SD) score | 2.23 (0.67) | 2.45 (0.51) | 2.52 (0.52) |
|
| 2.27 (0.61) | 2.39 (0.54) | 2.28 (0.63) |
|
|
|
|
| Ceiling effect (%) | 12% | 14% | 24% |
|
| 11% | 16% | 17% |
|
|
|
|
| Floor effect (%) | 0% | 0% | 0% |
|
| 0% | 0% | 0% |
|
|
|
|
| Overall |
|
|
| <.001 | .44 |
|
|
| .05 | N/A | .01 |
|
| Δ6-1 |
|
|
| .046 | .45 |
|
|
| N/A | N/A | .05 |
|
| Δ24-6 |
|
|
| .99 | N/A |
|
|
| N/A | N/A | .03 |
|
| Δ24-1 |
|
|
| <.001 | .43 |
|
|
| N/A | N/A | .01 |
|
|
|
|
|
|
|
|
| |||||
|
| Mean (SD) score | 2.36 (0.75) | 2.47 (0.70) | 2.53 (0.54) |
|
| 2.41 (0.70) | 2.43 (0.65) | 2.41 (0.69) |
|
|
|
|
| Ceiling effect (%) | 30% | 43% | 34% |
|
| 40% | 35% | 32% |
|
|
|
|
| Floor effect (%) | 5% | 2% | 0% |
|
| 0% | 0% | 0% |
|
|
|
|
| Overall |
|
|
| .14 | N/A |
|
|
| .80 | N/A | .22 |
|
| Δ6-1 |
|
|
| N/A | N/A |
|
|
| N/A | N/A | N/A |
|
| Δ24-6 |
|
|
| N/A | N/A |
|
|
| N/A | N/A | N/A |
|
| Δ24-1 |
|
|
| N/A | N/A |
|
|
| N/A | N/A | N/A |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
| Mean (SD) score | 2.27 (0.63) | 2.46 (0.51) | 2.53 (0.44) |
|
| 2.31 (0.59) | 2.40 (0.51) | 2.32 (0.58) |
|
|
|
|
| Ceiling effect (%) | 8% | 13% | 19% |
|
| 6% | 10% | 10% |
|
|
|
|
| Floor effect (%) | 0% | 0% | 0% |
|
| 0% | 0% | 0% |
|
|
|
|
| Overall |
|
|
| .01 | .44 |
|
|
| .21 | N/A | .01 |
|
| Δ6-1 |
|
|
| .07 | .44 |
|
|
| N/A | N/A | .05 |
|
| Δ24-6 |
|
|
| .84 | N/A |
|
|
| N/A | N/A | .04 |
|
| Δ24-1 |
|
|
| <.001 | .43 |
|
|
| N/A | N/A | .01 |
aN/A: not applicable; SRM: standardized response mean.